Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer's antibiotic Avelox has been shown in a study to be as effective as a high-dose rival drug combination in the treatment of severe community acquired pneumonia.
Subscribe to our email newsletter
According to Schering-Plough which markets the drug in the US, Avelox monotherapy at 400mg once daily is as effective as the high-dose combination of 500mg of levofloxacin taken twice daily plus 2g of ceftriaxone taken once daily in treating patients with the disease.
The study, dubbed MOTIV, showed no significant difference in clinical cure rates between the two competing regimens.
A total of 748 patients were enrolled in the study, of which 738 patients were randomized. Both treatments were well tolerated in the study, with similar adverse event profiles.
“The results of the MOTIV study are important because community-acquired pneumonia is a particular concern for people with chronic illnesses or impaired immune systems, and is a common cause of hospitalization worldwide,” said Dr Antoni Torres, professor of pulmonology at the University of Barcelona in Spain.